Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anagrelide and Mutational Status in Essential Thrombocythemia.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy - 1 Jun 2016

Iurlo Alessandra, Cattaneo Daniele, Orofino Nicola, Bucelli Cristina, Fabris Sonia, Cortelezzi Agostino

Abstract excerpt

BACKGROUND: Anagrelide is an orally active, quinazolone-derived, platelet-lowering agent that acts by blocking megakaryocyte maturation and polyploidization as well as proplatelet formation, and is currently indicated for second-line treatment of high-risk patients with essential thrombocythemia (ET) in Europe. In recent years various clinical trials have confirmed the safety and efficacy of this drug in ET, with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Platelet Aggregation Inhibitors

Share to Quinazolines

Share to Receptors, Thrombopoietin

Share to Thrombocythemia, Essential

Share to Treatment Outcome

Source

Identifiers

PMID: 27041108
DOI: 10.1007/s40259-016-0170-9

Genes

CALR
JAK2
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anagrelide and Mutational Status in Essential Thrombocythemia.PMID 27041108Read ↗

Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.Semantic proximity Read ↗

JAK2V617F, CALR and MPL515L/K mutations and plateletcrit in essential thrombocythemia: A single centre's experience.Semantic proximity Read ↗

[Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].Semantic proximity Read ↗

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.Semantic proximity Read ↗

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.Semantic proximity Read ↗

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.Semantic proximity Read ↗

JAK2 or CALR Mutations Status and Bone Marrow Histology in Patients with Essential Thrombocythemia in ChineseSemantic proximity Read ↗

[Clinical Characteristics and Bone Marrow Histopathology Features in Essential Thrombocythaemia Patients with Different Gene Mutation in China].Semantic proximity Read ↗

A rare CALR variant mutation and efficient peginterferon alfa-2a response in a patient with essential thrombocythemia.Semantic proximity Read ↗

Anagrelide and the CALR mutation allele burden in essential thrombocythemia.Semantic proximity Read ↗

Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.Semantic proximity Read ↗

Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.